Veeva price target raised to $290 from $280 at Piper Sandler

Piper Sandler raised the firm’s price target on Veeva (VEEV) to $290 from $280 and keeps an Overweight rating on the shares following Q3 results. The firm cited “solid execution” and increasing adoption intent across the “Top 20” biopharma firms for the price target raise.